UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 613

Sortiert nach

A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease

Travel medicine and infectious disease, 2020-05, Vol.35, p.101646-101646, Article 101646

2020

Volltextzugriff (PDF)

HIV‐protease inhibitors for the treatment of cancer: Repositioning HIV protease inhibitors while developing more potent NO‐hybridized derivatives?

International journal of cancer, 2017-04, Vol.140 (8), p.1713-1726

2017

Volltextzugriff (PDF)

Current evidence for the risk of PR prolongation, QRS widening, QT prolongation, from lopinavir, ritonavir, atazanavir, and saquinavir: A systematic review

Medicine (Baltimore), 2021-08, Vol.100 (31), p.e26787

2021

Volltextzugriff (PDF)

HIV protease inhibitor attenuated astrocyte autophagy involvement in inflammation via p38 MAPK pathway

Antiviral research, 2022-12, Vol.208, p.105463, Article 105463

2022

Volltextzugriff (PDF)

The use of a topical protease inhibitor, Saquinavir, to alleviate mouse papillomavirus-mediated anal disease

Virology (New York, N.Y.), 2022-11, Vol.576, p.96-104

2022

Volltextzugriff (PDF)

The Use of the Protease Inhibitor, Saquinavir, to Treat Anal Cancer Spheroids Derived From Human Papillomavirus Transgenic Mice

Diseases of the colon & rectum, 2023-03, Vol.66 (3), p.360

2023

Volltextzugriff (PDF)

Risk of diabetes mellitus in persons with and without HIV: a Danish nationwide population-based cohort study

PloS one, 2012-09, Vol.7 (9), p.e44575

2012

Volltextzugriff (PDF)

The HIV protease inhibitor Saquinavir attenuates sepsis-induced acute lung injury and promotes M2 macrophage polarization via targeting matrix metalloproteinase-9

Cell death & disease, 2021-01, Vol.12 (1), p.67-14, Article 67

2021

Volltextzugriff (PDF)

Quinolines and isoquinolines as HIV-1 inhibitors: Chemical structures, action targets, and biological activities

Bioorganic chemistry, 2023-07, Vol.136, p.106549-106549, Article 106549

2023

Volltextzugriff (PDF)

Anti-HIV drugs for cancer therapeutics: back to the future?

The lancet oncology, 2009, Vol.10 (1), p.61-71

2009

Volltextzugriff (PDF)

96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures

AIDS (London), 2006-03, Vol.20 (5), p.711-718

2006

Volltextzugriff (PDF)

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

AIDS (London), 1998-05, Vol.12 (7), p.F51-F58

1998

Volltextzugriff (PDF)

Twenty years of boosting antiretroviral agents: where are we today?

AIDS (London), 2015-11, Vol.29 (17), p.2229-2233

2015

Volltextzugriff (PDF)

In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells

Cell cycle (Georgetown, Tex.), 2011-02, Vol.10 (3), p.492-499

2011

Volltextzugriff (PDF)

Cathepsin L promotes Vascular Intimal Hyperplasia after Arterial Injury

Molecular medicine (Cambridge, Mass.), 2017-01, Vol.23 (1), p.92-100

2017

Volltextzugriff (PDF)

Therapeutic potential of nitric oxide-modified drugs in colon cancer cells

Molecular pharmacology, 2012-10, Vol.82 (4), p.700-710

2012

Volltextzugriff (PDF)

The effect of antiretrovirals on Plasmodium falciparum liver stages

AIDS (London), 2013-06, Vol.27 (10), p.1674-1677

2013

Volltextzugriff (PDF)

Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial

JAMA : the journal of the American Medical Association, 2002-07, Vol.288 (2), p.169

2002

Volltextzugriff (PDF)

Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir

AIDS (London), 2004-11, Vol.18 (17), p.2277-2284

2004

Volltextzugriff (PDF)

HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma

Nature medicine, 2002-03, Vol.8 (3), p.225-232

2002

Volltextzugriff (PDF)

Randomized Trial to Evaluate Indinavir/Ritonavir versus Saquinavir/Ritonavir in Human Immunodeficiency Virus Type 1–Infected Patients: The MaxCmin1 Trial

The Journal of infectious diseases, 2003-09, Vol.188 (5), p.635-642

2003

Volltextzugriff (PDF)

A Review of Low-Dose Ritonavir in Protease Inhibitor Combination Therapy

Clinical infectious diseases, 2003-06, Vol.36 (12), p.1585-1592

2003

Volltextzugriff (PDF)

New-onset saquinavir-induced diabetes

Diabetes care, 2013-12, Vol.36 (12), p.e199-e199

2013

Volltextzugriff (PDF)

Pharmacokinetic study of saquinavir 500 mg plus ritonavir (1000/100 mg twice a day) in HIV-positive pregnant women

Therapeutic drug monitoring, 2011-12, Vol.33 (6), p.772

2011

Volltextzugriff (PDF)

Saquinavir in steroid-dependent and -resistant nephrotic syndrome: a pilot study

Nephrology, dialysis, transplantation, 2012-05, Vol.27 (5), p.1902-1910

2012

Volltextzugriff (PDF)

1 – 25 von 613

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(469)
Mit Volltextzugriff
(435)

Publikationsform

Artikel
(602)
magazinearticle
(11)

Sprache

5 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(600)
Hiv Infections - Drug Therapy
(478)
Saquinavir - Therapeutic Use
(446)
Hiv Protease Inhibitors - Therapeutic Use
(444)
Science & Technology
(394)
Life Sciences & Biomedicine
(389)
Aids/hiv
(388)
Drug Therapy, Combination
(305)
Male
(259)
Infectious Diseases
(255)
Ritonavir - Therapeutic Use
(255)
Biological And Medical Sciences
(251)
Anti-Hiv Agents - Therapeutic Use
(250)
Medical Sciences
(250)
Adult
(238)
Female
(213)
Saquinavir
(206)
Pharmacology. Drug Treatments
(196)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(174)
Antiviral Agents
(170)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease

HIV‐protease inhibitors for the treatment of cancer: Repositioning HIV protease inhibitors while developing more potent NO‐hybridized derivatives?

Current evidence for the risk of PR prolongation, QRS widening, QT prolongation, from lopinavir, ritonavir, atazanavir, and saquinavir: A systematic review

HIV protease inhibitor attenuated astrocyte autophagy involvement in inflammation via p38 MAPK pathway

The use of a topical protease inhibitor, Saquinavir, to alleviate mouse papillomavirus-mediated anal disease

The Use of the Protease Inhibitor, Saquinavir, to Treat Anal Cancer Spheroids Derived From Human Papillomavirus Transgenic Mice

Risk of diabetes mellitus in persons with and without HIV: a Danish nationwide population-based cohort study

The HIV protease inhibitor Saquinavir attenuates sepsis-induced acute lung injury and promotes M2 macrophage polarization via targeting matrix metalloproteinase-9

Quinolines and isoquinolines as HIV-1 inhibitors: Chemical structures, action targets, and biological activities

Anti-HIV drugs for cancer therapeutics: back to the future?

96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

Twenty years of boosting antiretroviral agents: where are we today?

In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells

Cathepsin L promotes Vascular Intimal Hyperplasia after Arterial Injury

Therapeutic potential of nitric oxide-modified drugs in colon cancer cells

The effect of antiretrovirals on Plasmodium falciparum liver stages

Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial

Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir

HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma

Randomized Trial to Evaluate Indinavir/Ritonavir versus Saquinavir/Ritonavir in Human Immunodeficiency Virus Type 1–Infected Patients: The MaxCmin1 Trial

A Review of Low-Dose Ritonavir in Protease Inhibitor Combination Therapy

New-onset saquinavir-induced diabetes

Pharmacokinetic study of saquinavir 500 mg plus ritonavir (1000/100 mg twice a day) in HIV-positive pregnant women

Saquinavir in steroid-dependent and -resistant nephrotic syndrome: a pilot study

Suchergebnisse filtern